CORE--NEUROPATHOLOGY

$80,560P01FY2002AGNIH

Massachusetts General Hospital, Boston MA

Investigators

Linked publications & trials

Paper 36749854 Paper 30953760 Paper 26830138 Paper 26599050 Paper 26252541 Paper 25710492 Paper 25431646 Paper 25307057 Paper 25285942 Paper 24478794 Paper 23650207 Paper 23629586 Paper 23375563 Paper 22982484 Paper 21986342 Paper 21595698 Paper 21518999 Paper 21403019 Paper 21161449 Paper 19847047 Paper 19571734 Paper 19290745 Paper 19233293 Paper 19112067 Paper 19040786 Paper 18823230 Paper 18672473 Paper 18631748 Paper 18378553 Paper 18292383 Paper 18195145 Paper 18056553 Paper 17999200 Paper 17893294 Paper 17846109 Paper 17604351 Paper 17562935 Paper 17413317 Paper 17413017 Paper 17056633 Paper 17021177 Paper 16651008 Paper 16530430 Paper 16303318 Paper 16298252 Paper 16087905 Paper 16041286 Paper 15717023 Paper 15585477 Paper 15576857 Paper 15453969 Paper 15327037 Paper 15236399 Paper 15037694 Paper 14568509 Paper 12925361 Paper 12621314 Paper 12486265 Paper 12165365 Paper 11971085 Paper 11836778 Paper 11756667 Paper 11559958 Paper 11459114 Paper 11402113 Paper 10815133 Paper 10762153

Abstract

There are two overarching goals for the Neuropathology Core. The first involves neuropathological evaluation of brain tissue obtained at autopsy on subjects in the Program Project. These analyses will be performed: (1) to provide a neuropathological diagnosis on all subjects who come to autopsy, (2) to perform quantitative neuropathological data on all subject who come to autopsy, and (3) to perform biochemical analysis for Abeta and synaptophysin on the brain samples of all subjects who come to autopsy. In addition, Core D will evaluate Abeta 40 and Abeta42 in plasma samples that are collected annually, to determine if these measures can serve as biomarkers of 'conversion' to AD.

View original record on NIH RePORTER →